News
Helsinn closes financing agreement with Oberland Capital
Helsinn announces the appointment of Dr Melanie Rolli as Group Chief Executive Officer
Helsinn closes financing agreement with Oberland Capital

Sintetica establishes US entity
COMUNICATO STAMPA – Waldo Mossi eletto Vicepresidente di Farma Industria Ticino per il triennio 2022-2025
Comunicato Stampa “Farma Industria Ticino and Credit Suisse Award for best student”

Helsinn Healthcare SA signs exclusive license agreement with Juniper Biologics Pte. Ltd. for LEDAGA® (chlormethine) in Australia, Asia and the Middle East*

Helsinn presents newly available data on vepafestinib at IASLC 2022 World Conference on Lung Cancer

Linkedin